Education
About Us
Working with TipRanks
Follow Us
Cytek Biosciences (CTKB)
NASDAQ:CTKB
Total Valuation
Cytek Biosciences has a market cap or net worth of $492.53M. The enterprise value is $588.41M.
Market Cap$492.53M
Enterprise Value$588.41M
Share Statistics
Cytek Biosciences has 127,599,144 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding127,599,144
Owned by Insiders9.16%
Owned by Institutions0.08%
Financial Efficiency
Cytek Biosciences’s return on equity (ROE) is -0.02 and return on invested capital (ROIC) is -5.02%.
Return on Equity (ROE)-0.02
Return on Assets (ROA)-0.01
Return on Invested Capital (ROIC)-5.02%
Return on Capital Employed (ROCE)-0.05
Revenue Per Employee309.34K
Profits Per Employee-9.29K
Employee Count648
Asset Turnover0.40
Inventory Turnover2.04
Valuation Ratios
The current PE Ratio of Cytek Biosciences is -141.23. Cytek Biosciences’s PEG ratio is 1.41.
PE Ratio-141.23
PS Ratio0.00
PB Ratio2.15
Price to Fair Value2.15
Price to FCF38.90
Price to Operating Cash Flow33.50
PEG Ratio1.41
Income Statement
In the last 12 months, Cytek Biosciences had revenue of 200.45M and earned -6.02M in profits. Earnings per share was 0.00.
Revenue200.45M
Gross Profit111.11M
Operating Income-20.52M
Pretax Income-5.70M
Net Income-6.02M
EBITDA-20.52M
Earnings Per Share (EPS)0.00
Cash Flow
In the last 12 months, operating cash flow was 25.38M and capital expenditures -3.53M, giving a free cash flow of 21.84M billion.
Operating Cash Flow25.38M
Free Cash Flow21.84M
Free Cash Flow per Share0.17
Dividends & Yields
Cytek Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.56
52-Week Price Change-39.88%
50-Day Moving Average4.09
200-Day Moving Average5.38
Relative Strength Index (RSI)49.67
Average Volume (3m)830.83K
Important Dates
Cytek Biosciences upcoming earnings date is May 8, 2025, TBA Not Confirmed.
Last Earnings DateFeb 27, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Cytek Biosciences as a current ratio of 5.86, with Debt / Equity ratio of 1.91%
Current Ratio5.86
Quick Ratio5.21
Debt to Market Cap<0.01
Net Debt to EBITDA4.44
Interest Coverage Ratio-3.92
Taxes
In the past 12 months, Cytek Biosciences has paid 320.00K in taxes.
Income Tax320.00K
Effective Tax Rate-0.06
Enterprise Valuation
Cytek Biosciences EV to EBITDA ratio is -36.99, with an EV/FCF ratio of 34.73.
EV to Sales3.79
EV to EBITDA-36.99
EV to Free Cash Flow34.73
EV to Operating Cash Flow29.91
Balance Sheet
Cytek Biosciences has $277.86M in cash and marketable securities with $18.09M in debt, giving a net cash position of -$270.31M billion.
Cash & Marketable Securities$277.86M
Total Debt$18.09M
Net Cash-$270.31M
Net Cash Per Share-$2.12
Tangible Book Value Per Share$2.74
Margins
Gross margin is 62.90%, with operating margin of -10.24%, and net profit margin of -3.00%.
Gross Margin62.90%
Operating Margin-10.24%
Pretax Margin-2.84%
Net Profit Margin-3.00%
EBITDA Margin-10.24%
EBIT Margin-10.24%
Analyst Forecast
The average price target for Cytek Biosciences is $7.13, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$7.13
Price Target Upside84.72% Upside
Analyst ConsensusHold
Analyst Count4
Revenue Growth Forecast3.85%
EPS Growth Forecast49.09%